Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 680.00 |
Low | 680.00 |
Bid | -- |
Offer | -- |
Previous close | 680.00 |
Average volume | -- |
---|---|
Shares outstanding | 126.68m |
Free float | 125.31m |
P/E (TTM) | 22.97 |
Market cap | 7.50bn USD |
EPS (TTM) | 2.58 USD |
Data delayed at least 20 minutes, as of Sep 22 2023 12:30 BST.
More ▼
Press releases
- Global Cancer Rates Surge as Biotech Innovators Work on New Therapies
- Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis
- Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer
- Halozyme to Present at Upcoming Investor Conferences
- HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS
- Halozyme to Report Second Quarter 2024 Financial and Operating Results
- Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
More ▼